Moderna, Inc. (MRNA)

Moderna is a biotechnology company and pioneer in mRNA medicine, using its integrated mRNA, lipid nanoparticle (LNP) delivery, and manufacturing platform to develop vaccines and therapeutics across infectious disease, oncology, and rare disease. The company currently markets three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine), generating $1.9 billion in total 2025 revenue, primarily from COVID vaccine sales, with mNEXSPIKE now leading in the U.S. retail channel following its Q3 2025 launch. Its pipeline of 35 programs, six in late-stage development, spans three franchises: infectious disease vaccines (including seasonal flu candidate mRNA-1010, flu/COVID combination mRNA-1083, pandemic flu candidate mRNA-1018, norovirus candidate mRNA-1403, CMV, EBV, and HIV vaccines), oncology therapeutics (led by intismeran autogene/mRNA-4157, an individualized neoantigen therapy developed with Merck showing sustained recurrence-free survival benefit in melanoma across eight ongoing Phase 2/3 trials, plus cancer antigen therapy mRNA-4359), and rare disease therapeutics (propionic acidemia candidate mRNA-3927, which reached target enrollment and is now partnered with Recordati for late-stage development and commercialization, and methylmalonic acidemia candidate mRNA-3705, expected to enter registrational study in 2026).

Regulatory filings are under review for mRNA-1083 in Europe and Canada and for mRNA-1010 in the U.S., Europe, Canada, and Australia, with the FDA having accepted an amended BLA for mRNA-1010 after a prior Refusal-to-File, setting a PDUFA date of August 5, 2026. The company has built a global manufacturing network, including new facilities in the UK, Canada, and Australia for local vaccine access, and a Marlborough, Massachusetts facility purpose-built for intismeran production. Moderna's strategic priorities include driving commercial sales growth through geographic expansion and new launches, improving cost efficiency via manufacturing productivity and AI/digital tools, executing on its prioritized late-stage pipeline with anticipated 2026 data readouts, and continuing to advance early-stage oncology, rare disease, and infectious disease programs to expand and diversify its platform-driven portfolio.